Literature DB >> 1515985

New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification.

H Bülzebruck1, R Bopp, P Drings, E Bauer, S Krysa, G Probst, G van Kaick, K M Müller, I Vogt-Moykopf.   

Abstract

BACKGROUND AND METHODS: To validate the new TNM definitions for lung cancer (International Union Against Cancer [UICC] TNM classification, 4th edition, 1987), the data of 3823 patients were analyzed prospectively in terms of concordance between clinical (TNM) and pathologically confirmed classification (pTNM), the value of the various diagnostic techniques in estimating the pathologically confirmed classification, and the prognostic relevance of the new TNM definitions.
RESULTS: With regard to the primary tumor (T), clinical and pathologic classifications were identical in 63%; with regard to lymph node involvement (N), the agreement was 47%; for distant metastasis agreement occurred in 91% of cases and for the stages it occurred in 56%. As to the primary tumor (T), the accuracy of radiography (59%) was nearly identical to that of computed tomography (CT) (58%). Both techniques were less precise in determining the extent of lymph node involvement (CT, correct assessments in 50%; radiography, correct assessments in 43%). The statistically significant differences in the prognosis for the T, N, and M categories and for the stages and the categories of the new R classification could be confirmed. Allowance should be made for the different prognosis between T1N0M0 and T2N0M0 by the new Substages IA and Ib of Stage I.
CONCLUSIONS: By the new TNM definitions for bronchus carcinoma, international conformity became feasible and practical, and the improvement of its prognostic relevance provided a more reliable basis for establishing guidelines for individual oncologic concepts.

Entities:  

Mesh:

Year:  1992        PMID: 1515985     DOI: 10.1002/1097-0142(19920901)70:5<1102::aid-cncr2820700514>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Lung cancer . 3: Fluorescence bronchoscopy: clinical dilemmas and research opportunities.

Authors:  A K Banerjee; P H Rabbitts; J George
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 2.  [Endobronchial ultrasound in bronchial carcinoma].

Authors:  F J F Herth; H D Becker; R Eberhardt
Journal:  Radiologe       Date:  2004-05       Impact factor: 0.635

3.  Surveillance for the detection of early lung cancer in patients with bronchial dysplasia.

Authors:  Philip Jeremy George; Anindo K Banerjee; Catherine A Read; Caoihme O'Sullivan; Mary Falzon; Francesco Pezzella; Andrew G Nicholson; Penny Shaw; Geoff Laurent; Pamela H Rabbitts
Journal:  Thorax       Date:  2006-07-06       Impact factor: 9.139

4.  Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients.

Authors:  Alexander Lin; Charles Wood; Christine Hill-Kayser; Rosemarie Mick; Larry Kaiser; James Metz
Journal:  Exp Ther Med       Date:  2010-09-29       Impact factor: 2.447

5.  Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer.

Authors:  Zhu-Jun Liu; Jing Wang; Xi-Yin Wei; Peng Chen; Liu-Chun Wang; Li Lin; Bao-Cun Sun; Kai Li
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-14       Impact factor: 4.553

6.  EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells.

Authors:  Prasanthi Karna; Starlette M Sharp; Clayton Yates; Satya Prakash; Ritu Aneja
Journal:  Mol Cancer       Date:  2009-10-30       Impact factor: 27.401

7.  Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-12-01

Review 8.  [Pathology, classification, and staging of malignant lung tumors].

Authors:  K-M Müller; T Wiethege
Journal:  Radiologe       Date:  2004-05       Impact factor: 0.635

9.  Baseline FACT-G score is a predictor of survival for advanced lung cancer.

Authors:  M Dharma-Wardene; H J Au; J Hanson; D Dupere; J Hewitt; D Feeny
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

10.  ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.

Authors:  Jie Yang; Chunxu Yang; Shimin Zhang; Zijie Mei; Mingjun Shi; Shaoxing Sun; Liu Shi; Zhihao Wang; Yacheng Wang; Zhenzhen Li; Conghua Xie
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.